Lung Cancer Trial, Recruiting NCT06598839 Sponsor: Yousheng Mao Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06598839
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your lung cancer has been confirmed by a lab test to be stage I invasive non-small cell lung cancer (NSCLC), based on the most recent staging guidelines
  • Your tumor can be surgically removed
  • You are planned to have a specific type of lung surgery called a lobectomy (removal of a section of the lung) along with removal of nearby lymph nodes
  • You have not had any other cancer in the past and do not have another cancer at the same time
  • You have not received any cancer treatments or immune-boosting therapies before
  • You are generally healthy enough to have surgery, with your heart, lungs, liver, brain, and kidneys working well enough, and you are able to carry out daily activities with little to no limitation
  • You are between 18 and 75 years old
  • You are willing and able to sign a consent form and follow the study schedule and procedures

Who may not be able to join:

  • Your lung cancer has been confirmed as a non-invasive type, or you have small cell lung cancer, pre-cancerous lesions, or a benign (non-cancerous) growth
  • You have used immune-suppressing or immune-boosting medications after your diagnosis
  • You have a known or suspected autoimmune disease (where your immune system attacks your own body)
  • You are allergic to thymopeptides (a type of medication used in this trial)
  • You have other serious uncontrolled health conditions, including: a serious active infection; epilepsy requiring medication; kidney dialysis; wounds, ulcers, or bone fractures that are not healing; or a history of blood clots, stroke, or pulmonary embolism (blood clot in the lungs) within the six months before starting the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yousheng Mao, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

Phone: 8610-67781331

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Yousheng Mao
Registry
ClinicalTrials.gov
Start date
30 June 2024
Est. completion
30 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of CTCs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov